SCHEDULE: Intracoastal Capital Discloses 4.99% Stake in Genprex

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Genprex, Inc. common stock as of November 3, 2025.

Summary

• Reporting Persons (Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC) collectively hold 84,814 shares of Genprex, Inc. Common Stock.
• This represents 4.99% of the outstanding Common Stock as of November 3, 2025.
• The ownership consists of 16,960 shares directly held by Intracoastal and 67,854 shares issuable upon exercise of Intracoastal Warrant 1.
• The beneficial ownership percentage is capped at 4.99% due to blocker provisions in Intracoastal Warrant 1 and Intracoastal Warrant 2, preventing exercise beyond this threshold.
• Without these blocker provisions, the Reporting Persons would beneficially own 280,838 shares of Common Stock.
• The event requiring this filing was the execution of a Securities Purchase Agreement (SPA) with Genprex, Inc. on October 28, 2025, which was disclosed in an 8-K filing on October 29, 2025.

Sentiment

Score: 5

Explanation: Neutral. This is a standard disclosure of beneficial ownership, indicating an investment but not providing operational or financial performance details. The blocker provision is a common investor strategy.

Risks

• The existence of blocker provisions in warrants suggests a strategic effort by the investor to avoid triggering certain reporting or regulatory thresholds (e.g., 5% or 10% ownership), which could imply a desire to maintain flexibility or avoid perceived control.
• The company's stock could experience dilution if the warrants are fully exercised in the future, assuming the blocker provisions are removed or the outstanding share count increases significantly.

Future Outlook

N/A

Industry Context

This filing indicates an investment by a capital firm (Intracoastal Capital LLC) in Genprex, Inc., a biotechnology company. Such investments are common in the biotech sector, which often requires significant capital for research, development, and clinical trials. The use of warrants and blocker provisions is a typical mechanism for investors to manage their ownership stake and regulatory obligations.

Stakeholder Impact

• Shareholders: The investment by Intracoastal Capital LLC, through a Securities Purchase Agreement involving new share issuance and warrants, indicates a capital infusion for Genprex, which could support its operations and development. However, the issuance of new shares could also lead to dilution for existing shareholders.
• Company (Genprex, Inc.): The capital raise provides funding, which is crucial for biotechnology companies.

Key Dates

Keywords

Genprex Inc, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Equity Investment, SEC Filing, Biotechnology, Pharmaceuticals